Cargando…

CD39 as a marker of pathogenic CD8+ T cells in cancer and other chronic inflammatory diseases

Detalles Bibliográficos
Autores principales:	Canale, Fernando Pablo, Ramello, María Cecilia, Montes, Carolina Lucía
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978445/ https://www.ncbi.nlm.nih.gov/pubmed/29854871 http://dx.doi.org/10.18632/oncoscience.404

Ejemplares similares

CD39(+) conventional CD4(+) T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade
por: Bossio, Sabrina N., et al.
Publicado: (2023)

CD39 Expression Identifies Terminally Exhausted CD8(+) T Cells
por: Gupta, Prakash K., et al.
Publicado: (2015)

CD39-Expressing CD8(+) T Cells as a New Molecular Marker for Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma
por: Liu, Meitong, et al.
Publicado: (2023)

CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer
por: Zhu, Wenjie, et al.
Publicado: (2021)

CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39
por: Zhang, Xiao, et al.
Publicado: (2019)

CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer
por: Tallón de Lara, Paulino, et al.
Publicado: (2021)

Conversion of the CD8 lineage to CD4 T cells
por: Guzman, Maria P., et al.
Publicado: (2015)

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
por: Duhen, Thomas, et al.
Publicado: (2018)

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer
por: Workel, Hagma H., et al.
Publicado: (2020)

Low expression of CD39 and CD73 genes in centenarians compared with octogenarians
por: Crooke, Almudena, et al.
Publicado: (2017)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma
por: Dong, Dan-Ning, et al.
Publicado: (2021)

Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer
por: Lubbers, Joyce M., et al.
Publicado: (2022)

Unusual CD4(+)CD28(−) T Cells and Their Pathogenic Role in Chronic Inflammatory Disorders
por: Lee, Ga Hye, et al.
Publicado: (2016)

CD39 Regulation and Functions in T Cells
por: Timperi, Eleonora, et al.
Publicado: (2021)

The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia
por: Brachtl, Gabriele, et al.
Publicado: (2013)

The difference and relationship of CD4+ and CD8+ tumour infiltrating lymphocytes in lung adenocarcinoma
por: Zhang, Chaoting, et al.
Publicado: (2019)

CD49b, CD87, and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent Normal Fibroblasts in Murine Tumor Models
por: Agorku, David J., et al.
Publicado: (2019)

CD39 and control of cellular immune responses
por: Dwyer, Karen M., et al.
Publicado: (2007)

NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine
por: Bai, Aiping, et al.
Publicado: (2015)

IL‐12 and IL‐4 activate a CD39‐dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells
por: Noble, Alistair, et al.
Publicado: (2016)

PMN‐MDSCs‐induced accumulation of CD8+CD39+ T cells predicts the efficacy of chemotherapy in esophageal squamous cell carcinoma
por: Qin, Guohui, et al.
Publicado: (2020)

Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients
por: Shahbazi, Mehdi, et al.
Publicado: (2021)

Monitoring and characterizing soluble and membrane-bound ectonucleotidases CD73 and CD39
por: Goueli, Said A., et al.
Publicado: (2019)

CD39 and CD73 as Promising Therapeutic Targets: What Could Be the Limitations?
por: Battastini, Ana Maria Oliveira, et al.
Publicado: (2021)

CD39/CD73/A2AR pathway and cancer immunotherapy
por: Xia, Chenglai, et al.
Publicado: (2023)

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy
por: Jiang, Xuan, et al.
Publicado: (2023)

Exploring CD39 and CD73 Expression as Potential Biomarkers in Prostate Cancer
por: Gardani, Carla Fernanda Furtado, et al.
Publicado: (2023)

Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided “immune-hot” colorectal cancers
por: Talhouni, Shahd, et al.
Publicado: (2023)

Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults
por: Pastor, Lucía, et al.
Publicado: (2018)

LOW CD8+ COUNT CORRELATION WITH INFLAMMATORY MARKERS IN ACUTE COVID-19
por: ZIAD, MOHAMED, et al.
Publicado: (2022)

Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy
por: Duchateau, Lena, et al.
Publicado: (2019)

CD4(+)CD8(+) T follicular helper cells regulate humoral immunity in chronic inflammatory lesions
por: Murayama, Kosuke, et al.
Publicado: (2022)

CD39(+) regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function
por: Ahlmanner, Filip, et al.
Publicado: (2018)

The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition
por: Bauer, Arthur, et al.
Publicado: (2022)

The Role of Cluster of Differentiation 39 (CD39) and Purinergic Signaling Pathway in Viral Infections
por: Elsaghir, Alaa, et al.
Publicado: (2023)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells
por: Zhang, Yuhan, et al.
Publicado: (2023)

Divide, Conquer, and Sense: CD8(+)CD28(−) T Cells in Perspective
por: Arosa, Fernando A., et al.
Publicado: (2017)

Elderly CD8(+) T cells in the focus for immunotherapeutic approaches
por: Lis, Annette, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_udvrjcpn21dcac5ianh48nu1g9